SIA
VRTX icon

Strategic Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Sell
746
-63
-8% -$27.9K 0.02% 251
2026
Q1 		$362K Sell
809
-702
-46% -$327K 0.03% 250
2025
Q4 		$685K Sell
1,511
-139
-8% -$59.9K 0.06% 135
2025
Q3 		$646K Sell
1,650
-124
-7% -$51.8K 0.06% 136
2025
Q2 		$788K Buy
1,774
+39
+2% +$18K 0.08% 115
2025
Q1 		$841K Sell
1,735
-51
-3% -$23.8K 0.09% 119
2024
Q4 		$719K Sell
1,786
-1
-0.1% -$464 0.08% 139
2024
Q3 		$831K Sell
1,787
-4,005
-69% -$1.92M 0.09% 129
2024
Q2 		$2.71M Sell
5,792
-187
-3% -$81.2K 0.33% 47
2024
Q1 		$2.5M Buy
5,979
+67
+1% +$28.3K 0.32% 49
2023
Q4 		$2.41M Sell
5,912
-2,752
-32% -$1.02M 0.35% 50
2023
Q3 		$3.01M Sell
8,664
-7,990
-48% -$2.79M 0.5% 38
2023
Q2 		$5.86M Buy
16,654
+7,832
+89% +$2.64M 0.81% 22
2023
Q1 		$2.78M Buy
8,822
+2,912
+49% +$873K 0.5% 33
2022
Q4 		$1.71M Buy
5,910
+924
+19% +$282K 0.35% 51
2022
Q3 		$1.44M Buy
+4,986
New +$1.43M 0.33% 56

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Strategic Investment Advisors's VRTX Position: Q2 2026 in Review

Strategic Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 7.8% in Q2 2026, selling an estimated $27.9K and leaving 746 shares worth $371K. The position accounts for 0.02% of the portfolio, ranked #251.

Strategic Investment Advisors first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $5.86M in Q2 2023. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Strategic Investment Advisors held 746 shares of Vertex Pharmaceuticals worth $371K as of Q2 2026.
  • Strategic Investment Advisors sold 63 Vertex Pharmaceuticals shares in Q2 2026, an estimated $27.9K.
  • Vertex Pharmaceuticals made up 0.02% of Strategic Investment Advisors's portfolio in Q2 2026, its #251 holding.
  • Strategic Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Strategic Investment Advisors's Vertex Pharmaceuticals position peaked at $5.86M in Q2 2023.
  • 1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Strategic Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.